SGMT
SGMT clinical trials: Sagimet Biosciences Inc.
Every trial on ClinicalTrials.gov where Sagimet Biosciences Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 13
- Trials linked
- 10
- As lead sponsor
- 3
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
SGMT on the catalyst calendar · SGMT registry changes
- Primary completion Aug 2027Sponsor estimatePhase 3NCT07863193Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)Sagimet Biosciences Inc. · Acne VulgarisRecruitingSGMTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2027Sponsor estimatePhase 1NCT06989840Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without AcneSagimet Biosciences Inc. · AcneRecruitingSGMTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 20, 2025ActualPhase 1NCT07216313A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult ParticipantsSagimet Biosciences Inc. · HealthyCompletedSGMTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2026Sponsor estimatePhase 3NCT06692283A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASHSagimet Biosciences Inc. · MASLDWithdrawnSGMTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2030Sponsor estimatePhase 3NCT06594523A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 FibrosisSagimet Biosciences Inc. · MASHWithdrawnSGMTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2, 2023ActualPhase 2NCT04906421Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)Sagimet Biosciences Inc. · Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver DiseaseCompletedSGMTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2, 2021ActualPhase 2NCT03938246Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)Sagimet Biosciences Inc. · MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)CompletedSGMTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 18, 2023ActualPhase 1NCT05835180A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to...Sagimet Biosciences Inc. · Non-alcoholic SteatohepatitisCompletedSGMTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 21, 2022ActualPhase 1NCT05657834Open-label Study of the Absorption, Metabolism, and Excretion of [14C]TVB-2640 Following a Single Oral Dose in Healthy Male SubjectsSagimet Biosciences Inc. · Healthy VolunteersCompletedSGMTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2017ActualPhase 1NCT02223247A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid TumorsSagimet Biosciences Inc. · Solid Malignant TumorCompletedSGMTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 12, 2026ActualPhase 1NCT05743621Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate CancerWeill Medical College of Cornell University · Prostatic Neoplasms, Castration-ResistantActive, not recruitingSGMTCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 3, 2025ActualPhase 2NCT03808558Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung CarcinomasDavid E Gerber · KRAS Gene MutationActive, not recruitingSGMTCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 18, 2017ActualPhase 1/Phase 2NCT02948569Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic SyndromeUniversity of Missouri-Columbia · Metabolic SyndromeCompletedSGMTCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 13 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner